JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGON stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Buy rating due to a combination of factors that highlight CG Oncology’s promising developments in the treatment of non-muscle invasive bladder cancer (NMIBC). The company’s oncolytic immunotherapy, cretostimogene (creto), is showing significant progress, particularly in the BCG-Unresponsive NMIBC setting. Upcoming data presentations at the SUO 2025, including results from the BOND-003 and CORE-008 trials, are expected to provide comprehensive insights into creto’s efficacy, reinforcing its potential in high-risk NMIBC cases.
Moreover, CG Oncology’s accelerated completion of patient enrollment in the PIVOT-006 study, ahead of schedule, suggests that the company is on track to deliver early data readouts, which could further validate creto’s effectiveness. The absence of serious adverse events related to creto also supports its favorable safety profile. These factors, combined with the anticipation of several key trial readouts, contribute to the optimistic outlook and justify the Buy rating with a price target of $75.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.